ClinicalTrials.gg
RecruitingNCT07249905Updated Nov 6, 2026

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

A Phase 1/2 interventional study of MDX2003 in Lymphoma, Waldenström Macroglobulinemia (WM) and DLBCL - Diffuse Large B Cell Lymphoma, sponsored by ModeX Therapeutics, An OPKO Health Company. Recruiting at 7 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Primary conditionLymphoma, FollicularRegistry: LymphomaReclassifiedWhy we changed it
Registry
Lymphoma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Lymphoma, Follicular
Why
  1. The study's listed conditions name Lymphoma, Follicular, a narrower term within Lymphoma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ModeX Therapeutics, An OPKO Health Company (part of OPKO Health, Inc.) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 6, 2026First sites in Israel and Spain5 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
180
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 51 studies in Lymphoma, Follicular with a site in Israel — 9 open to participants now, 22 under way, 9 of them phase 3. Lymphoma, Follicular · Israel.

Planned enrollment
29th of 48
180 · median 250
Started
2026
with 3 others
Phase 1/2
3 of 51
2 open now
Primary completion
2028-01
later than 9 of 21 live
Registered
48th of 51
by date

Among the 51 studies in Lymphoma, Follicular with a site in Israel, this one is the 29th largest by planned enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2026, is one of 3 in phase 1/2, reaches primary completion later than 9 of the 21 other live ones, and was the 48th registered.

Lymphoma, Follicular

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

9 of the 51 studies in Lymphoma, Follicular with a site in Israel are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →

Who these studies take

Of the 226 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Lymphoma, Follicular with a site in Israel, or all of them as a file.
02

Study summary

This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2003 in patients with different types of lymphoma

03

Conditions studied

  • Lymphoma
  • Waldenström Macroglobulinemia (WM)
  • DLBCL - Diffuse Large B Cell Lymphoma
  • PMBCL
  • HGBCL
  • FL Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Follicular Lymphoma (FL)
04

In context

Lymphoma, Follicular Reclassified

1,893 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

This study's planned enrollment of 180 is above the median of 48 across 1,505 interventional studies indexed under Lymphoma, Follicular.

Browse Lymphoma, Follicular studies →

Lead sponsor

ModeX Therapeutics, An OPKO Health Company is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

First submitted after ModeX Therapeutics became part of OPKO Health, Inc..

Compared within Lymphoma, Follicular, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lymphoma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥ 18 years of age.
  • Participant has a confirmed diagnosis of large B-cell lymphoma (including DLBCL, high-grade B-cell lymphoma [HGBCL], primary mediastinal B-cell lymphoma [PMBCL], etc), FL, MCL, marginal zone lymphoma, transformation of indolent B-cell lymphoma, or lymphoplasmacytic lymphoma, including Waldenstrom macroglobulinemia.
  • Participant has or progressed on at least 2 .
  • (ECOG) performance status of 0 to 2.
  • All participants must have via computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT.
  • Documented CD19 or CD20 positivity of their B-cell neoplasm based on any representative pathology report from the past 3 months.
  • Adequate hematologic, hepatic and renal function.
  • All use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed .

Exclusion criteria

Exclusion Criteria:

  • Known or suspected history of hemophagocytic lymphohistiocytosis (HLH).
  • Unresolved toxicities from previous anticancer therapy.
  • Primary central nervous system (CNS) lymphoma or known CNS involvement with lymphoma.
  • Active medical condition requiring chronic systemic use (>10 mg/day prednisone or equivalent of >140 mg over the last 14 days) or therapy, within 6 months prior to the first dose of MDX2003.
  • Known positivity with (HIV), known active or C, or uncontrolled chronic or ongoing infection requiring intravenous treatment.
  • Participant has a history of allogenic tissue or solid organ transplant, with the exception of corneal transplants.
  • Known to allopurinol or rasburicase.
  • Participant has a seizure disorder requiring therapy at the time of screening (such as steroids or anti-epileptics).
  • Participant is not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Dose Escalation- Part A

    Participants with B-cell malignancies will receive MDX2003 as an intravenous (IV) infusion.

    Drug: MDX2003

  • Experimental
    Indication Optimization- Part B

    Participants with select B-cell malignancies will receive MDX2003 as an intravenous (IV) infusion.

    Drug: MDX2003

Interventions

  • DrugMDX2003

    MDX2003 intravenous infusion

07

What researchers measure

Primary outcomes

  1. Part A only- Identify the Maximum Tolerated Dose (MTD) for expansion for further development of MDX2003

    Maximum Tolerated Dose is determined following the evaluation of MDX2003 safety, including the incidences of dose-limiting toxicities (DLTs), MDX2003 anti-tumor activity, and MDX2003 pharmacokinetics/pharmacodynamics.

    Time frame: 28 days

  2. All Study Parts: Adverse Events (AEs)

    Incidence and severity of adverse events (AEs) and serious AEs (SAEs), including changes in clinical laboratory parameters, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v5.0 or American Society for Transplantation and Cellular Therapy (ASTCT) consensus grading criteria, including changes in clinical laboratory parameters.

    Time frame: Baseline until 90 days after the participant has the last dose of MDX2003

  3. Part B only- Assess the preliminary anti-lymphoma activity of MDX2003

    Objective response rate is defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) per Lugano Classification.

    Time frame: From date of enrollment until the end of treatment, up to approximately 6 months

Secondary outcomes

  1. All Study Parts: Measure of terminal half-life (t1/2) of MDX2003

    Characterize pharmacokinetic (PK) parameter t1/2 after intravenous infusion of MDX2003.

    Time frame: 6 months

  2. All Study Parts: Measure of area under the serum concentration-time curve (AUC) of MDX2003

    Characterize pharmacokinetic (PK) parameter AUC after intravenous infusion of MDX2003.

    Time frame: 6 months

  3. All Study Parts: Measure of time to maximum concentration (Tmax) of MDX2003

    Characterize pharmacokinetic (PK) parameter Tmax after intravenous infusion of MDX2003.

    Time frame: 6 months

  4. All Study Parts: Measure of maximum serum concentration (Cmax) of MDX2003

    Characterize pharmacokinetic (PK) parameter Cmax after intravenous infusion of MDX2003.

    Time frame: 6 months

  5. All Study Parts: Measure of volume of distribution (Vd) of MDX2003

    Characterize pharmacokinetic (PK) parameter Vd after intravenous infusion of MDX2003.

    Time frame: 6 months

  6. All Study Parts: Measure of system clearance of MDX2003

    Characterize pharmacokinetic (PK) parameter of system clearance after intravenous infusion of MDX2003.

    Time frame: 6 months

  7. All Study Parts: Evaluation of MDX2003 immunogenicity

    The presence and persistence of anti-MDX2003 antibodies.

    Time frame: 6 months

08

Study locations

7 of 7 sites recruiting
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jan 2028, 21 months after the start.

Of 43 industry-sponsored phase 1/2 interventional studies under Lymphoma, Follicular, half reached primary completion within 68 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 103. This study's planned 21 months is below that.

Counting every sponsor, half of 88 studies reached it within 73 months; a quarter within 50 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2025
First posted
Nov 25, 2025
StartActual
Apr 13, 2026
Primary completionEst.
Jan 2028
CompletionEst.
Apr 2030
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites added — first sites in Israel and Spain
Show 5 added (4 Israel, 1 Spain)
  • Rambam Medical Center · Haifa, Israel
  • Hadassah Medical Center · Jerusalem, Israel
  • Rabin Medical Center - Beilinson Hospital · Petah Tikva, Israel
  • Tel-Aviv Sourasky Medical Center · Tel Aviv, Israel
  • Virgen del Rocío University Hospital · Seville, Spain
across 2 updates, Oct 28, 2026 – Nov 6, 2026
Show all 2 updates
  1. Nov 6, 2026
    1 site added — first site in Spain
    Show site
    • Virgen del Rocío University Hospital · Seville, Spain
  2. Oct 28, 2026
    4 sites added — first site in Israel
    Show 4 added (4 Israel)
    • Rambam Medical Center · Haifa, Israel
    • Hadassah Medical Center · Jerusalem, Israel
    • Rabin Medical Center - Beilinson Hospital · Petah Tikva, Israel
    • Tel-Aviv Sourasky Medical Center · Tel Aviv, Israel
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07249905
Responsible party
Sponsor
First posted
Nov 25, 2025
Start date
Apr 13, 2026
Primary completion
Jan 2028 (estimated)
Completion
Apr 2030 (estimated)
Last update
Nov 6, 2026

Study contacts

ModeX Therapeutics, An OPKO Health Company
Contact
info@modextx.com
+1 857-233-9936

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion